Although PDK4-IN administration did not provide noticeable benefits, MIT treatment caused notable tumor shrinkage (58.8% volume reduction), validating the efficacy of MIT as a cytotoxic agent (Fig. 5b and Supplementary Fig. 4a). The gene discussed is PDK4; the disease is neoplasm.